Horizon Pharma (HZNP) PT Lowered to $17 at BMO Capital; '1Q Primary Care Disappointment Overshadows Orphan Progress'
Tweet Send to a Friend
BMO Capital lowered its price target on Horizon Pharma (NASDAQ: HZNP) to $17.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
